Synthesis and anti-inflammatory evaluation of new substituted 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 69, Issue 3, 2012, Pages 411-421

  Fahmy, Hoda H ^a   Khalifa, Nagy M ^a   Nossier, Eman S ^a   Abdalla, Mohamed M ^b   Ismai, Magda M F ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Hi Care Pharmaceuticals   (Egypt)

^c Al Azhar University   (Egypt)

Author keywords

Anti inflammatory; Pyrazole derivatives; Selective COX 2 inhibitor

Indexed keywords

1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOLE 4 CARBOXALDEHYDE; 2 AMINO 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXY PHENYL) 1H PYRAZOL 4 YL] 6 (THIEN 2 YL)PYRIDINE 3 CARBONITRILE; 3 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 2 CYANOACRYLOHYDRAZIDE; 3 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 4,5 DIHYDRO 5 OXO 1H PYRAZOL 4 CARBONITRILE; 3 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL]METHYLENEAMINO 1H PYRAZOL 5 (4H)ONE; 3 AMINO 4 [[1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL]METHYLENE] 1H PYRAZOL 5 (4H)ONE; 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2 DIHYDRO 2 OXO 6 (THIEN 2 YL) PYRIDINE 3 CARBONITRILE; 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 2 OXO INDENO[1,2 D]PYRIMIDINE 5 ONE; 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 2 THIOXO INDENO[1,2 D]PYRIMIDINE 5 ONE; 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4,7,8 HEXAHYDRO 2 OXOQUINAZOLIN 5 (6H)ONE; 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4,7,8 HEXAHYDRO 2 THIOXOQUINAZOLIN 5 (6H)ONE; 5 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 2H 1,2,4 TRIAZOLE 3 (4H)ONE; 5 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 2H 1,2,4 TRIAZOLE 3 (4H)THIONE; 5 ACETYL 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 3,4 DIHYDRO 6 METHYL PYRIMIDINE 2 (1H) ONE; 5 ACETYL 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 3,4 DIHYDRO 6 METHYL PYRIMIDINE 2 (1H) THIONE; 6 (4 CHLOROPHENYL) 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2 DIHYDRO 2 OXOPYRIDINE 3 CARBONITRILE; 6 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 2,4 DIOXO PYRIMIDINE 5 CARBONITRILE; 6 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 4 OXO 2 THIOXOPYRIMIDINE 5 CARBONITRILE; ANTIINFLAMMATORY AGENT; CELECOXIB; ETHYL 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 6 METHYL 2 OXOPYRIMIDINE 5 CARBOXYLATE; ETHYL 4 [1 (3 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 6 METHYL 2 THIOXOPYRIMIDINE 5 CARBOXYLATE; PROSTAGLANDIN INHIBITOR; SEMICARBAZIDE; THIOSEMICARBAZIDE; THIOUREA; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SCREENING; DRUG SYNTHESIS; INFRARED SPECTROPHOTOMETRY; MALE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ULCEROGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; MALE; PROSTAGLANDIN ANTAGONISTS; PYRAZOLES; RATS; RATS, WISTAR;

EID: 84863697832     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rapposelli S., Lapucci A., Minutolo F., Orlandini E., Ortore G., Pinza M., Balsamo A.: Farmaco 59, 25 (2004).
2. Sakya S., Hou X., Minich M., Rast B., Shavnya A., DeMello K., Cheng H. et al.: Bioorg. Med. Chem. Lett. 17, 1067 (2007).
3. Prasit P., Riendeau D.: Annu. Rep. Med. Chem. 32, 211 (1997).
4. Griswold D., Adams J.: Med. Res. Rev. 16, 181 (1996).
5. Balsamo I., Coletta A., Guglielmotti C., Landolfi F., Mancini A., Martinelli C., Milanese F. et al.: Eur. J. Med. Chem. 38, 157 (2003).
6. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A. et al.: Arthritis Rheum. 43, 370 (2000).
7. Penning T., Talley J., Bertenshaw S., Carter J., Collins P., Doctor S., Graneto M. et al.: J. Med. Chem. 40, 1347 (1997).
8. Talley J., Brown D., Carter J., Graneto M., Koboldt C., Masferrer J., Perkins W. et al.: J. Med. Chem. 43, 775 (2000).
9. Chan C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J. et al.: J. Pharmacol. Exp. Ther. 290, 551 (1999).
10. Bekhit A., Abdel-Aziem T.: Bioorg. Med. Chem. 12, 1935 (2004).
11. Rathish I., Javed K., Ahmad S., Bano S., Alam M., Pillai K., Singh S., Bagchi V.: Bioorg. Med. Chem. Lett. 19, 255 (2009).
12. Amir M., Kumar H., Khan S.: Bioorg. Med. Chem. Lett.18, 918 (2008).
13. Bansal E., Srivastava V., Kumar A.: Eur. J. Med. Chem. 36, 81 (2001).
14. Sauzem D., Santíanna G., Machado P., Duarte M., Ferreira J., Mello F., Beck P. et al.: Eur. J.Pharmacol.: 616, 91 (2009).
15. Milano J., Oliveira S., Rossato M., Sauzem P., Machado P., Beck P., Zanatta N. et al.: Eur. J. Pharmacol. 581, 86 (2008).
16. Tabarelli Z., Rubin M., Berlese D., Sauzem P., Missio T., Teixeira M., Sinhorin A. et al.: J. Med. Biol. Res. 37, 1531 (2004).
17. Godoy M., Fighera M., Souza F., Flores A., Rubin M., Oliveira M., Zanatta N. et al.: Eur. J. Pharmacol. 496, 93 (2004).
18. Revesz L., Blum E., Di Padova E., Buhl T., Feifel R., Gram H., Hiestand P. et al.: Bioorg. Med. Chem. Lett. 16, 262 (2006).
19. Gillespie SH.: Medical Microbiology Illustrated. p. 234, Butterworth Heinemann Ltd., Oxford 1994.
20. Winter C., Risely E., Nuss G.: J. Pharmacol. Exp. Ther. 141, 369 (1963).